Back to search results

Gamma-glutamylcysteine Supplementation for Parkinson's Disease

This study is looking at how a supplement called Gamma-glutamylcysteine (GGC) might help people with early Parkinson's disease (PD). Researchers want to see if taking 400 mg of GGC twice a day can increase levels of a natural antioxidant called glutathione in the brain and blood. They will also check if GGC affects movement, thinking skills, and gut health. To join, you need to be between 50 and 80 years old, have a confirmed PD diagnosis, and score 26 or higher on a memory test (MoCA). The study hopes to show that increasing glutathione levels can improve motor function. The current recruitment status is unclear.

Study design
This is an interventional study with a planned enrollment of 12 participants. It is a single-arm study, meaning all participants will receive the Gamma-glutamylcysteine supplement.
What's involved
Participants will take the Gamma-glutamylcysteine supplement for 12 months. Brain and blood measurements, as well as neuropsychological and motor function tests, will be done before and after supplementation.
Compensation
Not stated in the trial record.
Follow-up
Participants will be assessed at 12 months after starting the supplementation.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07064005

Enrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients.

Recruiting
PHASE1Ages 50–80InterventionalPrevention
Pravat Mandal
~12 participants
Updated 2026-05-04 on ClinicalTrials.gov
What's tested:Gamma- glutamylcysteine

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Changes in brain glutathione levels (mM) in people with Parkinson's Disease using Magnetic Resonance Spectroscopy compared to post-supplementation with GGC.
Measured over 12 months
+3 more outcomes measured

Conditions

Parkinsons Disease (PD)

Explore related trials

Parkinson Disease

NCT07064005

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • UPMC Presbyterian Hospital

    Pittsburgh, Pennsylvaniastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Pravat K Mandal, PHD · PRINCIPAL_INVESTIGATOR · University of Pittsburgh

Who to contact

Pravat K MANDAL, PHD
[email protected]
4126999561
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Confirmed Parkinson's Disease diagnosis.
Montreal Cognitive Assessment (MoCA) greater than or equal to 26.
Age (50 to 80 years of age).
Ability to read and write in English.

Exclusion

Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments in the eyes, skin, or body.
Subjects with claustrophobia.
Patients with a clinical diagnosis of Parkinson's disease dementia or dementia with Lewy bodies.
Subjects with a history of cancer.
Subjects with active psychosis or delirium.
Subjects with chronic kidney (creatinine \> 1.5mg/dL) or liver disease (AST ≥ 1.5 ULN; ALT ≥ 1.5 ULN) within 30 days prior to enrolment.
Subjects on antioxidant therapy (ashwagandha, gingko biloba or N-acetylcysteine) or illicit drug abuse/dependence (cocaine, heroin, marijuana, or fentanyl).
Subjects with previous traumatic head injury.

What this trial measures

  • Changes in brain glutathione levels (mM) in people with Parkinson's Disease using Magnetic Resonance Spectroscopy compared to post-supplementation with GGC.12 months

    MEGA-PRESS is a non-invasive imaging technique, to detect various neurochemical (e.g., Glutathione) using 1H MR spectroscopy.

  • Changes in brain iron levels (ppb) in people with Parkinson's Disease using Magnetic Resonance Imaging between pre and post GGC supplementation.12 months
  • Changes in baseline blood iron levels(ng/μl) in people with Parkinson's Disease12 months
  • Changes in baseline blood glutathione levels (µmol/l) in people with Parkinson's Disease compared to post-supplementation with GGC12 months